A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. This year’s metric has recorded a Price increase of 78.34%. However, over the past six months, we’ve seen a stronger performance of -0.88%. The price of NRSN leaped by -44.00% over the last 30 days. And in the last five days, it has fallen by -18.84%.
The stock price for NeuroSense Therapeutics Ltd (NRSN) currently stands at $1.12. The stock experienced a substantial increase in the last session, hitting $14.0 after starting at $1.12. The stock’s lowest price was $7.5 before closing at $1.2.
NeuroSense Therapeutics Ltd experienced a rather shaky stock market performance. The highest value in the past year was recorded at $2.60 on 06/12/25 and the lowest value was $0.64 on 08/13/24.
52-week price history of NRSN Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. NeuroSense Therapeutics Ltd’s current trading price is -56.92% away from its 52-week high, while its distance from the 52-week low is 76.24%. The stock’s price range during this time has been between $0.64 and $2.60. The trading volume for the Healthcare sector company’s shares reached about 0.59 million for the day, which was higher than the average daily volume of 0.37 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
NeuroSense Therapeutics Ltd (NRSN) has experienced a quarterly rise of 1.82% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 27.55M and boasts a workforce of 15 employees.
NeuroSense Therapeutics Ltd: Analysts’ Ratings Unveiled
As of right now, 2 analysts are rating NeuroSense Therapeutics Ltd as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.5174, with a change in price of +0.0491. Similarly, NeuroSense Therapeutics Ltd recorded 282,247 in trading volume during the last 100 days, posting a change of +4.58%.
NRSN’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NRSN stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.00.
NRSN Stock Stochastic Average
Today’s raw stochastic average for NeuroSense Therapeutics Ltd over the last 50 days is 7.50%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 10.91%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 17.30% and 21.93%, respectively.
